Consider HIV post-exposure prophylaxis
PEP should be started as soon as possible after significant exposure and continued for 28 days
Raltegravir (Isentress; RAL) 400 mg PO twice daily, plus
Truvada, 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
Other Considerations
If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP
Consider interactions with current medication interactions and contraindications, such as renal impairment with Truvada
For patients with creatinine clearance <60mL/min, consider Raltegravir 400mg PO twice daily, plus Zidovudine and Lamivudine with doses adjusted to the degree of renal dysfunction.
If the  source  exposure  does  report  exposure  to HIV  within the  last  6 weeks, HIV  RNA  PCR (HIV  viral  load)  should be  sent  along  with HIV  Ag/Ab screen on  the  source  and nPEP  should be  initiated for  the  exposed patient
If  both tests  result  not  detected  and nonreactive, respectively, nPEP  should  be  discontinued.
If the  source  is  willing  and  able  to be  tested and is  found to be  HIV-negative with  no  recent high-risk  exposures  to HIV, nPEP  is  not  indicated  and  should not  be  initiated, or  discontinued if  already  started.
The exposed  patient  still  warrants  baseline HIV  testing  and  should  be offered  baseline  and follow-up testing  for  other  transmissible  infections,  e.g. hepatitis  A, B, and C, syphilis, chlamydia, and gonorrhea.
For patients with creatinine clearance <60mL/min, consider Raltegravir 400mg PO twice daily, plus Zidovudine and Lamivudine with doses adjusted to the degree of renal dysfunction.
If  both tests  result  not  detected  and nonreactive, respectively, nPEP  should  be  discontinued.
If the  source  is  willing  and  able  to be  tested and is  found to be  HIV-negative with  no  recent high-risk  exposures  to HIV, nPEP  is  not  indicated  and  should not  be  initiated, or  discontinued if  already  started.
The exposed  patient  still  warrants  baseline HIV  testing  and  should  be offered  baseline  and follow-up testing  for  other  transmissible  infections,  e.g. hepatitis  A, B, and C, syphilis, chlamydia, and gonorrhea.
Not normally indicated, assuming patient has had full course of Hepatitis B vaccination (as all<unk>  workers should have)
If exposed-patient NOT already vaccinated, see Hepatitis B Post-Exposure Prophylaxis
If exposed-patient NOT already vaccinated, see Hepatitis B Post-Exposure Prophylaxis
No prophylaxis regimen has any benefit
Healthcare occupational exposure to blood or other body fluids
Laceration
Environmental exposure antibiotics
Retained foreign body
Bacteremia vs contaminated blood cultures
Skin and soft tissue infections
Multisystem inflammatory syndrome in children
Combative patient